List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1741244/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Induced pluripotent stem cells for modeling Smith–Magenis syndrome. , 2022, , 217-246.		1
2	AR cooperates with SMAD4 to maintain skeletal muscle homeostasis. Acta Neuropathologica, 2022, 143, 713-731.	7.7	6
3	Editorial Comment to Castrationâ€resistant prostate cancer diagnosed during leuprorelin treatment for spinal and bulbar muscular atrophy. IJU Case Reports, 2022, 5, 254-254.	0.3	1
4	Skeletal Muscle Pathogenesis in Polyglutamine Diseases. Cells, 2022, 11, 2105.	4.1	2
5	ClC-2-like Chloride Current Alterations in a Cell Model of Spinal and Bulbar Muscular Atrophy, a Polyglutamine Disease. Journal of Molecular Neuroscience, 2021, 71, 662-674.	2.3	13
6	Pharmacological inactivation of the prion protein by targeting a folding intermediate. Communications Biology, 2021, 4, 62.	4.4	30
7	Huntingtin-mediated axonal transport requires arginine methylation by PRMT6. Cell Reports, 2021, 35, 108980.	6.4	20
8	Clenbuterol-sensitive delayed outward potassium currents in a cell model of spinal and bulbar muscular atrophy. Pflugers Archiv European Journal of Physiology, 2021, 473, 1213-1227.	2.8	3
9	Decoding distinctive features of plasma extracellular vesicles in amyotrophic lateral sclerosis. Molecular Neurodegeneration, 2021, 16, 52.	10.8	19
10	Gene therapy with AR isoform 2 rescues spinal and bulbar muscular atrophy phenotype by modulating AR transcriptional activity. Science Advances, 2021, 7, .	10.3	20
11	A11â€Huntingtin-mediated axonal transport requires arginine methylation by PRMT6. , 2021, , .		0
12	Motor Neuron Diseases and Neuroprotective Peptides: A Closer Look to Neurons. Frontiers in Aging Neuroscience, 2021, 13, 723871.	3.4	5
13	Guidelines for the use and interpretation of assays for monitoring autophagy (4th) Tj ETQq1 1 0.784314 rgBT /C	verlock 10 9.1	) Tf 50 262 T 1,430
14	NURR1 and ERR1 Modulate the Expression of Genes of a <i>DRD2</i> Coexpression Network Enriched for Schizophrenia Risk. Journal of Neuroscience, 2020, 40, 932-941.	3.6	19
15	The E3 ubiquitin-protein ligase MDM2 is a novel interactor of the von Hippel–Lindau tumor suppressor. Scientific Reports, 2020, 10, 15850.	3.3	2
16	Insulin-like growth factor 1 signaling in motor neuron and polyglutamine diseases: From molecular pathogenesis to therapeutic perspectives. Frontiers in Neuroendocrinology, 2020, 57, 100821.	5.2	13
17	The pVHL neglected functions, a tale of hypoxia-dependent and -independent regulations in cancer. Open Biology, 2020, 10, 200109.	3.6	14
18	Disease mechanism, biomarker and therapeutics for spinal and bulbar muscular atrophy (SBMA). Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 1085-1091.	1.9	28

#	Article	IF	CITATIONS
19	Increased transcription of transglutaminase 1 mediates neuronal death in in vitro models of neuronal stress and Aβ1–42-mediated toxicity. Neurobiology of Disease, 2020, 140, 104849.	4.4	10
20	MEF2 impairment underlies skeletal muscle atrophy in polyglutamine disease. Acta Neuropathologica, 2020, 140, 63-80.	7.7	23
21	Polyglutamine-Expanded Androgen Receptor Alteration of Skeletal Muscle Homeostasis and Myonuclear Aggregation Are Affected by Sex, Age and Muscle Metabolism. Cells, 2020, 9, 325.	4.1	21
22	Transforming growth factor beta 1 signaling is altered in the spinal cord and muscle of amyotrophic lateral sclerosis mice and patients. Neurobiology of Aging, 2019, 82, 48-59.	3.1	15
23	Autophagic and Proteasomal Mediated Removal of Mutant Androgen Receptor in Muscle Models of Spinal and Bulbar Muscular Atrophy. Frontiers in Endocrinology, 2019, 10, 569.	3.5	22
24	Muscleblind acts as a modifier of FUS toxicity by modulating stress granule dynamics and SMN localization. Nature Communications, 2019, 10, 5583.	12.8	31
25	Insights into the genetic epidemiology of spinal and bulbar muscular atrophy: prevalence estimation and multiple founder haplotypes in the Veneto Italian region. European Journal of Neurology, 2019, 26, 519-524.	3.3	12
26	Pituitary Adenylyl Cyclase Activating Polypeptide (PACAP) Signaling and the Cell Cycle Machinery in Neurodegenerative Diseases. Current Pharmaceutical Design, 2019, 24, 3878-3891.	1.9	3
27	Beyond motor neurons: expanding the clinical spectrum in Kennedy's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 808-812.	1.9	48
28	T197. A DRD2 CO-EXPRESSION GENE SET ENRICHED FOR SCHIZOPHRENIA RISK GENES IS CHARACTERIZED BY A COMMON TRANSCRIPTIONAL REGULATION INVOLVING NURR1 TRANSCRIPTION FACTOR. Schizophrenia Bulletin, 2018, 44, S193-S193.	4.3	0
29	From gene to therapy in spinal and bulbar muscular atrophy: Are we there yet?. Molecular and Cellular Endocrinology, 2018, 465, 113-121.	3.2	18
30	A14â€Arginine methylation of huntingtin is a novel post-translational modification that impacts huntington's disease pathogenesis. , 2018, , .		0
31	Increased mitophagy in the skeletal muscle of spinal and bulbar muscular atrophy patients. Human Molecular Genetics, 2017, 26, ddx019.	2.9	37
32	Beta-agonist stimulation ameliorates the phenotype of spinal and bulbar muscular atrophy mice and patient-derived myotubes. Scientific Reports, 2017, 7, 41046.	3.3	26
33	Altered ionic currents and amelioration by IGF-1 and PACAP in motoneuron-derived cells modelling SBMA. Biophysical Chemistry, 2017, 229, 68-76.	2.8	17
34	The role of AR polyQ tract in male breast carcinoma: lesson from an SBMA case. Annals of Oncology, 2017, 28, 1160-1161.	1.2	1
35	Mutations in TGM6 induce the unfolded protein response in SCA35. Human Molecular Genetics, 2017, 26, 3749-3762.	2.9	36
36	Post-translational Modifications and Protein Quality Control in Motor Neuron and Polyglutamine Diseases. Frontiers in Molecular Neuroscience, 2017, 10, 82.	2.9	49

#	Article	IF	CITATIONS
37	No effect of <i><scp>AR</scp></i> polyG polymorphism on spinal and bulbar muscular atrophy phenotype. European Journal of Neurology, 2016, 23, 1134-1136.	3.3	8
38	Adenylyl cyclase activating polypeptide reduces phosphorylation and toxicity of the polyglutamine-expanded androgen receptor in spinobulbar muscular atrophy. Science Translational Medicine, 2016, 8, 370ra181.	12.4	37
39	Mitochondrial implications in bulbospinal muscular atrophy (Kennedy disease). Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2016, 17, 112-118.	1.7	6
40	Introduction to the Special Issue on Spinal and Bulbar Muscular Atrophy. Journal of Molecular Neuroscience, 2016, 58, 313-316.	2.3	4
41	Rescue of Metabolic Alterations in AR113Q Skeletal Muscle by Peripheral Androgen Receptor Gene Silencing. Cell Reports, 2016, 17, 125-136.	6.4	42
42	Non-neural phenotype of spinal and bulbar muscular atrophy: results from a large cohort of Italian patients. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 810-816.	1.9	59
43	In Vitro and In Vivo Modeling of Spinal and Bulbar Muscular Atrophy. Journal of Molecular Neuroscience, 2016, 58, 365-373.	2.3	18
44	Glycolytic-to-oxidative fiber-type switch and mTOR signaling activation are early-onset features of SBMA muscle modified by high-fat diet. Acta Neuropathologica, 2016, 132, 127-144.	7.7	74
45	Aberrant Autophagic Response in The Muscle of A Knock-in Mouse Model of Spinal and Bulbar Muscular Atrophy. Scientific Reports, 2015, 5, 15174.	3.3	47
46	210th ENMC International Workshop: Research and clinical management of patients with spinal and bulbar muscular atrophy, 27–29 March, 2015, Naarden, The Netherlands. Neuromuscular Disorders, 2015, 25, 802-812.	0.6	16
47	Protein Arginine Methyltransferase 6 Enhances Polyglutamine-Expanded Androgen Receptor Function and Toxicity in Spinal and Bulbar Muscular Atrophy. Neuron, 2015, 85, 88-100.	8.1	89
48	Serine phosphorylation and arginine methylation at the crossroads to neurodegeneration. Experimental Neurology, 2015, 271, 77-83.	4.1	26
49	Identification and Expression of Acetylcholinesterase in Octopus vulgaris Arm Development and Regeneration: a Conserved Role for ACHE?. Molecular Neurobiology, 2015, 52, 45-56.	4.0	25
50	Revisiting default mode network function in major depression: evidence for disrupted subsystem connectivity. Psychological Medicine, 2014, 44, 2041-2051.	4.5	122
51	Androgens affect muscle, motor neuron, and survival in a mouse model of SOD1-related amyotrophic lateral sclerosis. Neurobiology of Aging, 2014, 35, 1929-1938.	3.1	31
52	Skeletal muscle as an emerging therapeutic target in spinal and bulbar muscular atrophy. Clinical Investigation, 2014, 4, 293-295.	0.0	0
53	New Routes to Therapy for Spinal and Bulbar Muscular Atrophy. Journal of Molecular Neuroscience, 2013, 50, 514-523.	2.3	17
54	Androgen-dependent impairment of myogenesis in spinal and bulbar muscular atrophy. Acta Neuropathologica, 2013, 126, 109-121.	7.7	41

#	Article	IF	CITATIONS
55	Protein Arginine Methyltransferase 1 and 8 Interact with FUS to Modify Its Sub-Cellular Distribution and Toxicity In Vitro and In Vivo. PLoS ONE, 2013, 8, e61576.	2.5	80
56	Differential autophagy power in the spinal cord and muscle of transgenic ALS mice. Frontiers in Cellular Neuroscience, 2013, 7, 234.	3.7	53
57	MpzR98C arrests Schwann cell development in a mouse model of early-onset Charcot–Marie–Tooth disease type 1B. Brain, 2012, 135, 2032-2047.	7.6	61
58	The E3 ubiquitin ligase TRIM11 mediates the degradation of congenital central hypoventilation syndrome-associated polyalanine-expanded PHOX2B. Journal of Molecular Medicine, 2012, 90, 1025-1035.	3.9	17
59	Cell-autonomous and non-cell-autonomous toxicity in polyglutamine diseases. Progress in Neurobiology, 2012, 97, 152-172.	5.7	39
60	Insulinlike Growth Factor (IGF)-1 Administration Ameliorates Disease Manifestations in a Mouse Model of Spinal and Bulbar Muscular Atrophy. Molecular Medicine, 2012, 18, 1261-1268.	4.4	56
61	CAG repeat length in androgen receptor gene is not associated with amyotrophic lateral sclerosis. European Journal of Neurology, 2012, 19, 1373-1375.	3.3	9
62	Catechol-O-Methyl Transferase Modulates Cognition in Late Life: Evidence and Implications for Cognitive Enhancement. CNS and Neurological Disorders - Drug Targets, 2012, 11, 195-208.	1.4	12
63	Neurotoxic effects of androgens in spinal and bulbar muscular atrophy. Frontiers in Neuroendocrinology, 2011, 32, 416-425.	5.2	50
64	B2 attenuates polyglutamineâ€expanded androgen receptor toxicity in cell and fly models of spinal and bulbar muscular atrophy. Journal of Neuroscience Research, 2010, 88, 2207-2216.	2.9	26
65	Calcium signalling-dependent mitochondrial dysfunction and bioenergetics regulation in respiratory chain Complex II deficiency. Cell Death and Differentiation, 2010, 17, 1855-1866.	11.2	41
66	Native Functions of the Androgen Receptor Are Essential to Pathogenesis in a Drosophila Model of Spinobulbar Muscular Atrophy. Neuron, 2010, 67, 936-952.	8.1	150
67	Post-translational modifications of expanded polyglutamine proteins: impact on neurotoxicity. Human Molecular Genetics, 2009, 18, R40-R47.	2.9	67
68	Mitochondrial abnormalities in spinal and bulbar muscular atrophy. Human Molecular Genetics, 2009, 18, 27-42.	2.9	171
69	Overexpression of IGF-1 in Muscle Attenuates Disease in a Mouse Model of Spinal and Bulbar Muscular Atrophy. Neuron, 2009, 63, 316-328.	8.1	205
70	Ablation of the UPR-Mediator CHOP Restores MotorÂFunction and Reduces Demyelination inÂCharcot-Marie-Tooth 1B Mice. Neuron, 2008, 57, 393-405.	8.1	245
71	Akt blocks ligand binding and protects against expanded polyglutamine androgen receptor toxicity. Human Molecular Genetics, 2007, 16, 1593-1603.	2.9	137
72	Different Intracellular Pathomechanisms Produce Diverse <i>Myelin Protein Zero</i> Neuropathies in Transgenic Mice. Journal of Neuroscience, 2006, 26, 2358-2368.	3.6	144

MARIA PENNUTO

#	Article	IF	CITATIONS
73	Taipoxin Induces Synaptic Vesicle Exocytosis and Disrupts the Interaction of Synaptophysin I with VAMP2. Molecular Pharmacology, 2005, 67, 1901-1908.	2.3	28
74	Synaptophysin: leading actor or walk-on role in synaptic vesicle exocytosis?. BioEssays, 2004, 26, 445-453.	2.5	296
75	Snake presynaptic neurotoxins with phospholipase A2 activity induce punctate swellings of neurites and exocytosis of synaptic vesicles. Journal of Cell Science, 2004, 117, 3561-3570.	2.0	63
76	Synaptophysin I Controls the Targeting of VAMP2/Synaptobrevin II to Synaptic Vesicles. Molecular Biology of the Cell, 2003, 14, 4909-4919.	2.1	104
77	Fluorescence Resonance Energy Transfer Detection of Synaptophysin I and Vesicle-associated Membrane Protein 2 Interactions during Exocytosis from Single Live Synapses. Molecular Biology of the Cell, 2002, 13, 2706-2717.	2.1	58
78	NGF-dependent and tissue-specific transcription ofvgfis regulated by a CREB-p300 and bHLH factor interaction. FEBS Letters, 2002, 510, 50-56.	2.8	24
79	Neurite Extension Occurs in the Absence of Regulated Exocytosis in PC12 Subclones. Molecular Biology of the Cell, 1999, 10, 2919-2931.	2.1	43
80	Interplay of the E Box, the Cyclic AMP Response Element, and HTF4/HEB in Transcriptional Regulation of the Neurospecific, Neurotrophin-Inducible <i>vgf</i> Geneâ€. Molecular and Cellular Biology, 1997, 17, 1244-1253.	2.3	27
81	Huntingtin-Mediated Axonal Transport Requires Arginine Methylation by PRMT6. SSRN Electronic Journal, 0, , .	0.4	2